Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2016-02-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
关于第一大股东的一致行动人名称变更的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the name change of the largest shareholder's concerted actor, with no mention of financial data, report attachments, or regulatory certifications. It is a shareholder-related notification but does not indicate a change in shareholding levels or capital structure. It is not a full report or financial statement. The document is brief and serves as a regulatory announcement about shareholder information. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2016-02-23 Chinese
2015年度业绩预告
Earnings Release Classification · 90% confidence The document is a 2015 annual performance forecast (业绩预告) for Jiangsu Sihuan Bio-pharmaceutical Co., Ltd. It covers the full fiscal year from January 1, 2015 to December 31, 2015, and provides estimated net profit and earnings per share figures, indicating a loss. It explicitly states that the forecast is unaudited and preliminary, with final data to be disclosed in the 2015 annual report. The document is short (1117 characters) and serves as a performance forecast announcement rather than a full financial report. This type of document is typically classified as an Earnings Release (ER) because it announces key financial results highlights for a period, even though it is a forecast rather than final results. It is not an Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. It is not a Report Publication Announcement (RPA) because it contains substantive financial forecast data, not just a notice of report availability. Therefore, the best fit is Earnings Release (ER). FY 2015
2016-01-27 Chinese
2015年第三次临时股东大会的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality and validity of the procedures and results of the 2015 third extraordinary general meeting (临时股东大会) of Jiangsu Sihuan Pharmaceutical Co., Ltd. It details the convening, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or management discussion but focuses on the legal compliance and validity of the shareholders' meeting process and resolutions. This type of document is a legal opinion related to a shareholders' meeting, which is not a full annual or interim report, nor an earnings release or management report. It is also not a simple announcement of voting results but a legal opinion on the meeting's legality. Given the content and nature, it fits best under Legal Proceedings Report (LTR), which covers updates on significant legal matters involving the company, including legal opinions on corporate governance events such as shareholder meetings.
2015-12-24 Chinese
2015年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2015 third extraordinary general meeting of shareholders of Jiangsu Sihuan Bioengineering Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals, and legal opinions on the meeting's validity. The content focuses on the voting outcomes and shareholder decisions rather than presenting financial data or management discussion. It is not a full annual or interim report, nor an earnings release or management report. It is not a proxy solicitation or a remuneration report. The document is clearly a formal announcement of voting results from a shareholders' meeting, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters but contains substantive voting results, so it is not merely a report publication announcement. Therefore, the classification is DVA with high confidence.
2015-12-24 Chinese
关于召开2015年第三次临时股东大会的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about the convening of the 2015 third extraordinary general meeting of shareholders for Jiangsu Sihuan Bioengineering Co., Ltd. It includes information about the meeting date, voting methods (both onsite and online), agenda items to be voted on, registration procedures, and voting instructions. There is no financial data or results reported, nor is it a transcript or presentation. It is not a report publication announcement since it contains substantive details about the meeting itself rather than just announcing a report's availability. The document is clearly a notice related to a shareholders' meeting, specifically a notice of the meeting and instructions for voting. This fits the category of "Declaration of Voting Results & Voting Rights Announcements (DVA)" or possibly a meeting notice. However, since it is a "提示性公告" (a notice or reminder announcement) about the meeting and voting procedures, and not the actual voting results, it is best classified as a Regulatory Filing (RNS) because it does not report voting results but announces the meeting and voting process. Given the detailed nature and the focus on the meeting and voting instructions, the best fit is Regulatory Filings (RNS).
2015-12-21 Chinese
独立董事提名人声明
Board/Management Information Classification · 95% confidence The document is a public statement by a nominator regarding the nomination of an independent director candidate for the company's board. It contains detailed declarations about the nominee's qualifications, compliance with regulatory requirements, and independence criteria. There is no financial data, no report of financial results, no voting results, no management changes announcement, and no mention of any report publication or regulatory filing. The content is focused on board/management information specifically about the nomination of a board member. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is 2622 characters, which is relatively short but contains substantive content about management nomination rather than a mere announcement or certification.
2015-12-10 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.